How glucagon-like peptide 1 receptor agonists work
Open accessThe DOI matches its Crossref record; 99 of the 99 references it cites were found in a registry or an index.
Abstract
In recent years, glucagon-like peptide 1 receptor agonists (GLP-1RAs) have become central in the treatment of type 2 diabetes (T2D). In addition to their glucose-lowering properties with low risk of hypoglycaemia, GLP-1RAs reduce body weight and show promising results in reducing cardiovascular risk and renal complications in high-risk individuals with T2D. These findings have changed guidelines on T2D management over the last years, and GLP-1RAs are now widely used in overweight patients with T2D as well as in patients with T2D and cardiovascular disease regardless of glycaemic control. The currently available GLP-1RAs have different pharmacokinetic profiles and differ in their ability to improve glycaemia, reduce body weight and in their cardio- and renal protective potentials. Understanding how these agents work, including insights into their pleiotropic effects on T2D pathophysiology, may improve their clinical utilisation and be useful for exploring other indications such as non-alcoholic steatohepatitis and neurodegenerative disorders. In this review, we provide an overview of approved GLP-1RAs, their clinical effects and mode of action, and we offer insights into the potential of GLP-1RAs for other indications than T2D. Finally, we will discuss the emerging data and therapeutic potential of using GLP-1RAs in combinations with other receptor agonists.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures



Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“GLP-1RAs mimic the action of endogenous GLP-1, activating GLP-1R, thereby enhancing insulin secretion, inhibiting glucagon release, delaying gastric emptying, and reducing food intake through central appetite suppression.8–10”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [10]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Yaşlı Kadınlarda Üreme Sağlığı
Kokanalı, D., & Engin Üstün, Y. (n.d.) · DergiPark (Istanbul University) · Cited by 170,090
Home visits: a strategy to improve newborn survival - Authors' reply
(2008) · Americanae (AECID Library) · doi:10.1016/s0140 · Cited by 22,524
Correspondence - Tranexamic acid for traumatic brain injury
(2005) · London School of Economics and Political Science Theses Online (London School of Economics and Political Science) · doi:10.1016/s0140-6736 · Cited by 11,894
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
Marso, S. P., Daniels, G. H., Brown-Frandsen, K., Kristensen, P., Mann, J. F. E., Nauck, M. A., Nissen, S. E., Pocock, S., Poulter, N. R., Ravn, L. S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1603827 · Cited by 7,629
Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
Marso, S. P., Bain, S. C., Consoli, A., Eliaschewitz, F. G., Jódar, E., Leiter, L. A., Lingvay, I., Rosenstock, J., Seufert, J., Warren, M. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1607141 · Cited by 6,900
Self-citationOnce-Weekly Semaglutide in Adults with Overweight or Obesity
Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2032183 · Cited by 5,205
The Physiology of Glucagon-like Peptide 1
Holst, J. J. (2007) · Physiological Reviews · doi:10.1152/physrev.00034.2006 · Cited by 3,371
Gerstein, H. C., Colhoun, H. M., Dagenais, G. R., Diaz, R., Lakshmanan, M., Pais, P., Probstfield, J., Riesmeyer, J. S., Riddle, M. C., Rydén, L., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31149-3 · Cited by 3,163
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
Pfeffer, M. A., Claggett, B., Diaz, R., Dickstein, K., Gerstein, H. C., Køber, L. V., Lawson, F. C., Ping, L., Wei, X., Lewis, E. F., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1509225 · Cited by 2,409
Armstrong, M. J., Gaunt, P., Aithal, G. P., Barton, D., Hull, D., Parker, R., Hazlehurst, J. M., Guo, K., Abouda, G., Aldersley, M. A., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00803-x · Cited by 2,203
Research works printed but not linked: 1
- [89]A study of Tirzepatide (LY3298176) compared with dulaglutide on major cardiovascular events in participants with Type 2 diabetes (SurPASS-CVOT). (available at: https://clinicaltrials.gov/ct2/show/NCT04255433) 37758044
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“3,4 10 These mechanisms make GLP-1RAs powerful tools for controlling blood glucose and improving metabolic syndrome.”
BackgroundCoskun, T., Urva, S., Roell, W. C., Qu, H., Loghin, C., Moyers, J. S., O’Farrell, L. S., Briere, D. A., Sloop, K. W., Thomas, M. K., et al. (2022) · Cell Metabolism · doi:10.1016/j.cmet.2022.07.013 · Cited by 316
Reich, N., & Hölscher, C. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.970925 · Cited by 248
Horn, D. B., Almandoz, J. P., & Look, M. (2022) · Postgraduate Medicine · doi:10.1080/00325481.2022.2051366 · Cited by 114
GLP-1 agonist to treat obesity and prevent cardiovascular disease: what have we achieved so far
Pedrosa, M. R., Franco, D. R., Gieremek, H. W., Vidal, C. M., Bronzeri, F., de Cassia Rocha, A., de Carvalho Cara, L. G., Fogo, S. L., & Eliaschewitz, F. G. (2022) · Current Atherosclerosis Reports · doi:10.1007/s11883-022-01062-2 · Cited by 68
GLP-1RA Use and Thyroid Cancer Risk
Brito, J. P., Herrin, J. S., SWARNA, K. S., Ospina, N. S., Montori, V. M., Toro-Tobón, D., Umpierrez, G. E., Galindo, R. J., Deng, Y., Mickelson, M. M., et al. (2025) · JAMA Otolaryngology–Head & Neck Surgery · doi:10.1001/jamaoto.2024.4852 · Cited by 76
Scheen, A. J. (2024) · Drugs · doi:10.1007/s40265-024-02090-9 · Cited by 59
Pharmacological Support for the Treatment of Obesity—Present and Future
Kosmalski, M., Deska, K., Bąk, B., Różycka-Kosmalska, M., & Pietras, T. (2023) · Healthcare · doi:10.3390/healthcare11030433 · Cited by 68
The future of incretins in the treatment of obesity and non-alcoholic fatty liver disease
Andreasen, C. R., Andersen, A., & Vilsbøll, T. (2023) · Diabetologia · doi:10.1007/s00125-023-05966-9 · Cited by 44
Self-citationAndreasen, C. R., Andersen, A., Knop, F. K., & Vilsbøll, T. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14500 · Cited by 38
Self-citationDong, S., & Sun, C. (2022) · Frontiers in Endocrinology · doi:10.3389/fendo.2022.1032199 · Cited by 37
Capuccio, S., Scilletta, S., Rocca, F. L., Miano, N., Marco, M. D., Bosco, G., Barbagallo, F. D. G., Scicali, R., Piro, S., & Pino, A. D. (2024) · Biomolecules · doi:10.3390/biom14060687 · Cited by 48
Shah, V. N., Peters, A. L., Umpierrez, G. E., Sherr, J. L., Akturk, H. K., Aleppo, G., Bally, L., Cengiz, E., Cinar, A., Dungan, K., et al. (2025) · Journal of Diabetes Science and Technology · doi:10.1177/19322968241291512 · Cited by 36
“17,19 The potential glycemic benefits of treatment with GLP-1RAs in T1D may be mediated by effects on (1) the pancreas (decreased glucagon secretion in everyone and increased insulin secretion in those with remaining functioning beta-cells), (2) the central nervous system (reduced intake of food…”
Glucagon-Like Peptide-1 Receptor Agonists and Thyroid Cancer: A Narrative Review
Espinosa De Ycaza, A. E., Brito, J. P., McCoy, R. G., Shao, H., & Singh Ospina, N. (2024) · Thyroid · doi:10.1089/thy.2023.0530 · Cited by 37
“6,28,29 The GLP-1 has a regulatory effect in multiple organs, including the liver, brain, pancreas, gastrointestinal tract, kidney, and muscle.”
Novel Protein Therapeutics Created Using the Elastin-Like Polypeptide Platform
Bidwell, G. L. (2021) · Physiology · doi:10.1152/physiol.00026.2021 · Cited by 31
Kunutsor, S. K., & Seidu, S. (2025) · Drugs · doi:10.1007/s40265-025-02263-0 · Cited by 45
“Their primary glucose-lowering effects stem from enhancing glucose-dependent insulin secretion by pancreatic β-cells and suppressing glucagon secretion from α-cells, thereby reducing hepatic glucose production [21, 30, 31].”
Sass, M. R., Klausen, M. K., Schwarz, C. R., Rasmussen, L., Giver, M. E. B., Hviid, M., Schilling, C., Zamorski, A., Jensen, A., Gefke, M., et al. (2025) · JAMA Psychiatry · doi:10.1001/jamapsychiatry.2025.3639 · Cited by 45
Self-citationAn Approach to the Management of Diabetes Mellitus in Cirrhosis: A Primer for the Hepatologist
Puri, P., & Kotwal, N. (2021) · Journal of Clinical and Experimental Hepatology · doi:10.1016/j.jceh.2021.09.010 · Cited by 31
Hallmarks of Appetite: A Comprehensive Review of Hunger, Appetite, Satiation, and Satiety
Garutti, M., Sirico, M., Noto, C., Foffano, L., Hopkins, M., & Puglisi, F. (2025) · Current Obesity Reports · doi:10.1007/s13679-024-00604-w · Cited by 35
“Several GOAT inhibitors are under development aimed at reducing the orexigenic behavior induced by ghrelin [16].”
InfluentialBader, S., Bhatti, R., Mussa, B. M., & Abusanana, S. (2024) · Women s Health · doi:10.1177/17455057241234530 · Cited by 46
“18,17,19,20 Long-acting liraglutide and short-acting exenatide have recently been demonstrated for the management of PCOS, 21–28 as it has significant effect on weight reduction and favorable outcomes on metabolic and endocrine parameters.”
BackgroundMalarvannan, M., Ravichandiran, V., & Paul, D. (2024) · Journal of Chromatography A · doi:10.1016/j.chroma.2024.465226 · Cited by 21
Nerild, H. H., Brønden, A., Gether, I. M., Hellmann, P. H., Baekdal, M., Gillum, M. P., Svenningsen, J. S., Hartmann, B., Rathor, N., Angelene, H., et al. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15017 · Cited by 17
Self-citationGLP-1 receptor agonists as promising disease-modifying agents in WFS1 spectrum disorder
Panfili, E., Frontino, G., & Pallotta, M. T. (2023) · Frontiers in Clinical Diabetes and Healthcare · doi:10.3389/fcdhc.2023.1171091 · Cited by 16
Dharia, A., Desai, D., & Desai, K. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2025.02.005 · Cited by 18
Ahmad, N., Alruwayyes, A., AlArjani, A., Tawhari, A. M., Aldosri, A., Alahmari, A., & Balaha, M. F. H. (2026) · Medicine · doi:10.1097/md.0000000000047994 · Cited by 18
“39–41] Given the growing prevalence of obesity and its related complications, effective pharmaceutical therapies are important.”
Liraglutide Protects Against Diastolic Dysfunction and Improves Ventricular Protein Translation
Rutledge, C. A., Enriquez, A., Redding, K., Lopez, M. A., Mullett, S. J., Gelhaus, S. L., Jurczak, M. J., Goetzman, E. S., & Kaufman, B. A. (2023) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-023-07482-9 · Cited by 13
“GLP-1 is an incretin hormone released in the intestine that stimulates insulin secretion and lowers blood sugar [9, 10].”
Semaglutide - properties, action and chromatographic analysis
Wasilewska, B., & Petruczynik, A. (2025) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-025-01711-8 · Cited by 13
“GLP-1 receptor agonists are categorized in two groups based on their duration of action [22]: – short-acting GLP-1RAs: lixisenatide, exenatide (twice daily).”
Alenezi, B. T., Elfezzani, N., Uddin, R., Patel, H., Chester, S., Abdelmaksoud, A., Hussein, M. H., Zaitone, S. A., Fawzy, M. S., Aiash, H., et al. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13164896 · Cited by 13
“Further research is needed to elucidate the specific mechanisms underlying the differential effects of individual GLP-1R agonists and their clinical significance [27].”
BackgroundBridging the Gap: A Literature Review of Advancements in Obesity and Diabetes Mellitus Management
Pop, G. N., Manole, F., Buleu, F. N., Motofelea, A. C., Bircea, S., Popa, D. I., Motofelea, N., & Pîrvu, C. A. (2024) · Applied Sciences · doi:10.3390/app14156565 · Cited by 12
Repurposing the familiar: Future treatment options against chronic kidney disease
Bhadange, R., & Gaikwad, A. B. (2025) · Journal of Pharmacy and Pharmacology · doi:10.1093/jpp/rgaf002 · Cited by 9
Nunns, M., Febrey, S., Buckland, J., Abbott, R. A., Whear, R., Bethel, A. C., Boddy, K., Shaw, L., Coon, J. T., & Meléndez‐Torres, G. J. (2025) · Health Technology Assessment · doi:10.3310/skht8119 · Cited by 10
Paggers, L., Mesotten, D., & Stragier, H. (2024) · European Journal of Anaesthesiology · doi:10.1097/eja.0000000000002103 · Cited by 8
Basolo, A., Paolucci, G., Piaggi, P., Angeli, V., Genzano, S. B., Fierabracci, P., Vignali, E., Bologna, C., Salvetti, G., Chiovato, L., et al. (2025) · Journal of Endocrinological Investigation · doi:10.1007/s40618-025-02717-y · Cited by 10
“Liraglutide, a GLP-1 receptor agonist [6], has been extensively used for the treatment of obesity due to its ability to induce clinically meaningful weight loss in individuals with overweight or obesity [9, 34 , 35].”
Obstructive Sleep Apneas and Cardiovascular Diseases
Castiglione, V., Morfino, P., Fabiani, I., Gentile, F., Airò, E., Volpi, B., Cardinale, D. M., Passino, C., Giannoni, A., & Emdin, M. (2026) · Clocks & Sleep · doi:10.3390/clockssleep8020028 · Cited by 7
“GLP-1RAs promote insulin secretion, inhibit glucagon release, delay gastric emptying, reduce central appetite drive, and exert systemic anti-inflammatory effects [163,164].”
Glucagon-like peptide-1 receptor agonists: What ophthalmologists need to know
Bala, S., Allan, K. C., Decker, N. L., Abbass, N. J., Joo, J. H., Zhao, A., Talcott, K. E., & Rachitskaya, A. V. (2025) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2025.12.007 · Cited by 7
A case series of incidents reported to webAIRS relating to glucagon-like peptide 1 agonist use
Lam, C. Y., Lin, D., & Endlich, Y. (2025) · Anaesthesia and Intensive Care · doi:10.1177/0310057x241311597 · Cited by 5
Minerva, F. (2025) · Bioethics · doi:10.1111/bioe.70068 · Cited by 8
Benefits of Supplementing a GLP-1 Type Medication With Physical Activity
Ablah, E. A., Imboden, M. T., Zendell, A. L., Hosking, M., Anderson, R. E., VanHoose, K., Peterson, N. E., Wojcik, J. R., Pronk, N. P., Harber, M., et al. (2025) · American Journal of Health Promotion · doi:10.1177/08901171251357130 · Cited by 3
Perioperative Considerations for Patients on GLP1 Agonists
VanderWielen, B. A., & Beam, W. B. (2024) · Advances in Anesthesia · doi:10.1016/j.aan.2024.07.002 · Cited by 3
Çelik, M. N., & Uluğ, E. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01961-9 · Cited by 2
“M.N. Çelik and E. Ulug”
Heinonen, S., Karppinen, J. E., Saarinen, T., Groop, P.-H., Juuti, A., Holst, J. J., & Pietiläinen, K. H. (2026) · International Journal of Obesity · doi:10.1038/s41366-025-02000-3 · Cited by 3
“RYGB elicited a more pronounced early postprandial GLP-1 and glucose responses than OAGB, suggesting differential metabolic responses between the procedures that may in fl uence surgical outcomes and potential patient selection.”
Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) for Obesity and Symptoms in Menopause: A Review
Graczyk, N., & Bisschops, J. (2026) · Cureus · doi:10.7759/cureus.101693 · Cited by 3
Safety and efficacy of tirzepatide in transplant recipients: a systematic review and meta-analysis
Provenzani, A., Mancuso, B., Stitch, R., Tuzzolino, F., Giusti, M. A., & Mattina, A. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1735987 · Cited by 2
“Glucagon-like peptide-1 (GLP-1) is an incretin hormone secreted in response to elevated plasma glucose concentrations associated with food intake (Zheng et al., 2024; Andreasen et al., 2021).”
GLP-1 receptor agonists in stroke prevention: a narrative review on emerging therapeutic frontiers
Chikatimalla, R., Shah, A., Shah, T., Perry, G., Banker, H., Aggarwal, K., & Jain, R. (2026) · Annals of Medicine · doi:10.1080/07853890.2026.2660386 · Cited by 4
“These medications provide several benefits to the body: they boost insulin release when blood sugar is high, lower glucagon production, slow down gastric emptying and help reduce hunger by targeting the GLP-1 receptors in the brain [13–15].”
Charting New Territories in Obesity Management- Traditional Techniques to Tirzepatide
Fareed, A., Ghanem, L., Vaid, R., Iftikhar, Z., Rehman, A. U., Sarwar, A., & Asif, M. I. (2024) · Endocrine Practice · doi:10.1016/j.eprac.2024.09.004 · Cited by 4
Exploring Conformational Transitions in Biased and Balanced Ligand Binding of GLP-1R
Xu, M., Vogel, H., & Yuan, S. (2025) · Molecules · doi:10.3390/molecules30153216 · Cited by 3
“…the past few decades, numerous GLP-1RAs, such as semaglutide and liraglutide, have been developed, featuring intrinsic modification of the native GLP-1 peptide to imitate the pharmacological profile of GLP-1, while providing resistance to degradation by the enzyme dipeptidyl peptidase-4 [11–13].”
Kuo, N. I.-H., Hill, F. R., Arnott, C. G., Douglas, K. A., Barbieri, S., Ferdousi, S., Gandomkar, Z., Luxan, B. G., Woodward, M., & Jorm, L. R. (2026) · Heart Lung and Circulation · doi:10.1016/j.hlc.2025.09.012 · Cited by 1
Computational phenotyping of effort-based decision-making in type-2 diabetes on and off semaglutide
Mehrhof, S. Z., Fleming, H. A., & Nord, C. L. (2026) · Neuropsychopharmacology · doi:10.1038/s41386-026-02433-y · Cited by 1
“…in the type-2 diabetes, on semaglutide group were randomized to be tested on different days: one day after their weekly semaglutide injection (when treatment concentration is highest) or one day before (i.e., six days after their injection, when treatment concentration is reduced by half [31]).”
Liu, X., Xiong, B., Yang, R., Wang, H., & Liu, Y. (2026) · Endocrine Connections · doi:10.1530/ec-26-0280 · Cited by 1
“They also act through receptor or non-receptor pathways to inhibit hepatic glucose output, increase insulin sensitivity, suppress appetite, and delay gastric emptying, thereby promoting weight loss (19, 20, 21).”
Utilizing Semaglutide for Addressing Type-2 Diabetes and Obesity
Gupta, R., & Sharma, S. (2025) · Current Signal Transduction Therapy · doi:10.2174/0115743624346660250317013032 · Cited by 2
En quoi la prise en charge de l’hypertendu diabétique est-elle différente?
Teso, A. D., Lamine, F., Zanchi, A., & Wuerzner, G. (2022) · JMIG · doi:10.53738/revmed.2022.18.795.1710
Nielsen, T. A. (2023) · VBN Forskningsportal (Aalborg Universitet) · doi:10.54337/aau588597746
Stakhneva, E. M., Kuzminykh, N. A., Scherbakova, L. V., Kashtanova, E. V., Polonskaya, Y. V., Шрамко, В. С., Garbuzova, E. V., Sadovski, E. V., & Ragino, Y. I. (2023) · Kardiologiia · doi:10.18087/cardio.2023.11.n2492
Non‐insulin Parenteral Therapies
Vilsbøll, T., Christensen, M., Andersen, A., & Knop, F. K. (2024) · Wiley eBooks · doi:10.1002/9781119697473.ch36
Self-citationLange, A. H., Pedersen, M. G., Ellegaard, A., Nerild, H. H., Brønden, A., Sonne, D. P., & Knop, F. K. (2024) · European Journal of Endocrinology · doi:10.1093/ejendo/lvae153
Self-citationCardiovascular Toxicity in Diabetes Mellitus: Focus on Diabetogenic and Anti-diabetogenic Agents
Radisavljevic, N. M., Mutavdžin, S., & Djuric, D. M. (2025) · Advances in biochemistry in health and disease · doi:10.1007/978-3-031-90598-8_9
Diabetes Mellitus Type 2 and Cardiovascular Disease
Schmidt, E. A., Riess, J., Niebauer, J., Diem, G., & Niederseer, D. (2025) · Springer eBooks · doi:10.1007/978-3-031-95754-3_7
Advancing Drug Discovery through Molecular Dynamics Simulations: A Comprehensive Approach
Shtaiwi, A., Yamari, I., Chtita, S., & Adnan, R. (2025) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9798898812164125080006 · Cited by 1
Buran, K., & Kalay, Ş. (2026) · Journal of Research in Pharmacy · doi:10.12991/jrespharm.1822102
Effects of Semaglutide on Weight and Insulin Requirements in Two Adolescents With Type 1 Diabetes
Andreasen, C. R., Vilsbøll, T., Aistrup, M. Ø., & Kloppenborg, J. T. (2026) · PEDIATRICS · doi:10.1542/peds.2025-074286
Self-citationKrogh, L. S. L., Hansen, M. B., Bergmann, N. C., Hansen, C. P., Hartmann, B., Holst, J. J., Knop, F. K., Lund, A., & Gasbjerg, L. S. (2026) · Diabetes Obesity and Metabolism · doi:10.1111/dom.70940 · Cited by 1
“The glucose-lowering effect of GLP-1 and GLP-1R agonists is partly ascribed to their effect on insulin and glucagon secretion in patients with type 2 diabetes [33, 34].”
Self-citationJun, J. E., Oh, D.-H., Jeong, I., Ryu, H., Hwang, Y., Ahn, K. J., Chung, H. Y., & Kim, K. P. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1843595 · Cited by 1
Ravi, T., Dash, K., Barman, D. K., Kwon, H., Mishra, M., & Sahoo, H. (2026) · Biopolymers · doi:10.1002/bip.70113
Liu, H., 张庆红, Du, M., Hao, J., 牛玉梅, You, H., Cao, D., Tang, R., 杨艳艳, Wei, X., et al. (2026) · Clinical Nutrition · doi:10.1016/j.clnu.2026.106740
Safety of glucagon-like peptide-1 receptor agonists in neuroendocrine neoplasms
Rajan, L., Hofland, J., Mulugeta, E., & de Herder, W. W. (2026) · European Journal of Endocrinology · doi:10.1093/ejendo/lvag135
Porwolik, A., Porwolik, H., Cyran, P., Szydłowski, R., Bodera, M., & Skotarski, M. (2026) · International Journal of Innovative Technologies in Social Science · doi:10.31435/ijitss.2(50).2026.5185
Tirzepatide and the risk of asthma exacerbations in patients with type 2 diabetes
Liao, K., Kuo, C.-Y., Wu, J., Hsu, W., Tsai, Y., & Lai, C. (2026) · Frontiers in Endocrinology · doi:10.3389/fendo.2026.1928877
Hassan, A., Farooq, Q. U. A., Parwesh, F., Rasul, M., Masood, A., Aftab, H., Riaz, H., Mahmood, A., Malik, M. A., Rehman, A. U., et al. (2026) · F1000Research · doi:10.12688/f1000research.186847.1
Religa, P., Pieczynska, M. D., Łazarczyk, M., Kapoor, B., Logesh, R., Babiaka, S. B., Poznański, P., Mickael, M., Lagoa, R., Sacharczuk, M., et al. (2026) · Nutrients · doi:10.3390/nu18172852
“Secreted GLP-1 enhances glucose-dependent insulin secretion, suppresses glucagon release, slows gastric emptying, and promotes satiety, collectively limiting postprandial glucose excursions [73].”
GLP-1 Receptor Agonists: The Next Multifunctional Class of Drugs
MARBADE, S. (2026) · International Journal of Medical and Health Sciences · doi:10.64823/ijmhs.2601007
“It induces insulin release from pancreatic β cells [7], inhibits glucagon release from α cells, slows gastric emptying and suppresses appetite by activating specific GLP-1 receptors [5].”
Mahmood, T., Myrtziou, I., & Kanakis, I. (2026) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-026-02089-x
“GLP-1 receptor agonists (GLP-1RAs) lower glucose by stimulating glucose-dependent insulin secretion, suppressing glucagon secretion, and delaying gastric emptying; they also reduce appetite, energy intake, and body weight [10 , 11].”
Metadata
- Authors
- Andreasen, C. R., Andersen, A., Knop, F. K., & Vilsbøll, T.
- Affiliations
- University of Copenhagen (DK)
- Corresponding author
- Vilsbøll, Tina
- Venue
- Endocrine Connections
- Publisher
- Bioscientifica
- Published
- 2021-07-01
- Volume
- 10
- Issue
- 7
- Pages
- R200-R212
- ISSN
- 2049-3614 (ISSN-L)
- PMC
- PMC8346189
- OpenAlex
- W3171499734
- Cited by
- 71
- References
- 99
- Citations by year
- 2026: 22 · 2025: 18 · 2024: 15 · 2023: 7 · 2022: 6 · 2021: 3
- FWCI
- 1.19
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Endocrine Connections (publishedVersion, cc-by-nc)
- PubMed Central (publishedVersion, cc-by-nc)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion, cc-by-nc)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Funders
- Amgen
- Eli Lilly and Company
- AstraZeneca
- Sanofi
- Gilead Sciences
- Steno Diabetes Center Copenhagen (SDCC 3.F CMP)
- Novo Nordisk
- Novo Nordisk Fonden (NNF15OC0016230, NNF12OC1015904, NNF16OC0020224, NNF20SA0062832, NNF17OC0028300, NNF17OC0029438)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Keywords
- GLP-1 receptor agonists, type 2 diabetes, blood glucose reduction, weight loss, cardiovascular risk reduction, renal protection, pharmacokinetics, pleiotropy, nonalcoholic steatohepatitis, neurodegenerative diseases, combination therapy, receptor agonists
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.